Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atacicept for prevention of new flares after recent systemic lupus erythematosus flare
2007-003698-13Phase 2Completed
- Sponsor
- Merck Serono
- Start
- Dec 2007
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Atacicept with Placebo (2 arms). Primary endpoint: Proportion of subjects experiencing a new flare during the 52-week treatment period. Started Dec 2007; status: completed.
02
Drugs
atacicept
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2007-003698-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003698-13.